Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

June 6, 2017

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib (Kisqali) plus letrozole (Femara) in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.